PROSPECTUS SUPPLEMENT

COMBINED SUPPLEMENT 5/2014



BARCLAYS BANK PLC

(Incorporated with limited liability in England and Wales)

This prospectus supplement dated 2 July 2014 (the "**Prospectus Supplement**") is supplemental to and must be read in conjunction with each of the following registration document (the "**Registration Document**") and base prospectuses (the "**Base Prospectuses**" and each a "**Base Prospectus**") as prepared by Barclays Bank PLC its capacity as issuer (the "**Issuer**").

Registration Document	Description	Date of approval
Registration Document	Registration Document 1/2014	3 June 2014
Base Prospectus	Description	Date of approval
GSSP Base Prospectus 8 ("GSSP Base Prospectus 8")	Rate and Inflation Index Linked Securities	23 January 2014
iPath [®] Commodity Index Linked Exchange Traded Notes ("iPath [®] Commodity Index Linked")	Commodity Index Linked Exchange Trades Notes	5 June 2014
GSSP Base Prospectus 2 ("GSSP Base Prospectus 2")	Equity Linked Securities	6 June 2014
GSSP Base Prospectus 5 ("GSSP Base Prospectus 5")	Warrant Linked Securities	10 June 2014

This Prospectus Supplement constitutes a (i) registration document supplement in respect of the Registration Document and a (ii) base prospectus supplement in respect of each of the Base Prospectuses, in each case for the purposes of Directive 2003/71/EC (and amendments thereto) (the "**Prospectus Directive**") and for the purpose of Section 87G of the UK Financial Services and Markets Act 2000 ("**FSMA**").

The purpose of this Prospectus Supplement is to disclose certain significant new factors relating to the Issuer and its subsidiary undertakings that are capable of affecting the assessment of securities issued pursuant to any Base Prospectus.

Each of iPath® Commodity Index Linked, GSSP Base Prospectus 2 and GSSP Base Prospectus 5 incorporates the Registration Document by reference. GSSP Base Prospectus 8 does not incorporate the Registration Document by reference.

The Registration Document and each of the Base Prospectuses shall be supplemented as follows:

(a) Amendments in relation to regulatory matters

(i) Registration Document, iPath® Commodity Index Linked, GSSP Base Prospectus 2 and GSSP Base Prospectus 5:

In respect of each of the Registration Document, iPath® Commodity Index Linked, GSSP Base Prospectus 2 and GSSP Base Prospectus 5, the information appearing in 'The Issuer and the Group - Legal, Competition and Regulatory Matters' is updated by including the following additional information:

"Alternative Trading Systems and High-Frequency Trading

The SEC and the New York State Attorney General (NYAG) have been investigating a range of issues associated with alternative trading systems (ATSs) and the activities of high-frequency traders. The Group has been providing information to the authorities in response to their enquiries (the "ATSs and HFT Proceedings").

On 25 June 2014, the NYAG filed a complaint against Barclays PLC and Barclays Capital Inc. in the Supreme Court of the State of New York alleging, amongst other things, that Barclays PLC and Barclays Capital Inc. engaged in fraud and deceptive practices in connection with LX Liquidity Cross, the Group's SEC-registered ATS. The NYAG complaint seeks unspecified monetary damages and injunctive relief."

(ii) GSSP Base Prospectus 8:

In respect of GSSP Base Prospectus 8, the information appearing in 'The Issuer and the Group – Competition and Regulatory Matters' is updated by including the following information:

"Alternative Trading Systems and High-Frequency Trading

The SEC and the New York State Attorney General (NYAG) have been investigating a range of issues associated with alternative trading systems (ATSs) and the activities of high-frequency traders. Barclays PLC and its subsidiary undertakings have been providing information to the authorities in response to their enquiries.

On 25 June 2014, the NYAG filed a complaint against Barclays PLC and Barclays Capital Inc. in the Supreme Court of the State of New York alleging, amongst other things, that Barclays PLC and Barclays Capital Inc. engaged in fraud and deceptive practices in connection with LX Liquidity Cross, the Group's SEC-registered ATS. The NYAG complaint seeks unspecified monetary damages and injunctive relief."

(b) Amendments to 'Legal Proceedings'

(i) Registration Document, iPath® Commodity Index Linked, GSSP Base Prospectus 2 and GSSP Base Prospectus 5:

In respect of each of the Registration Document, iPath® Commodity Index Linked, GSSP Base Prospectus 2 and GSSP Base Prospectus 5, the information appearing in 'General Information – Legal Proceedings' is updated by including the following additional information:

"Legal Proceedings

Save as disclosed in respect of the Citi Proceedings, ADS Proceedings, and the RMBS Proceedings (in each case under the section headed, "Legal, Competition and Regulatory Matters" above), and the Devonshire Proceedings, LIBOR Proceedings, FX Trading Proceedings, Benchmark Proceedings, FERC Proceedings, BDC Finance Proceedings, CDS Proceedings, Qatar Holding Proceedings and

ATSs and HFT Proceedings (in each case under the section headed, "Regulatory Inquiries" above), there are no, and have not been, any governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware), which may have or have had during the 12 months preceding the date of this Registration Document, a significant effect on the financial position or profitability of the Issuer and/or the Bank Group."

(ii) GSSP Base Prospectus 8:

In respect of GSSP Base Prospectus 8, the information appearing in 'Information relating to the Issuer – Legal Proceedings' is updated by including the following additional information:

"Legal Proceedings

Save as disclosed under 'The Issuer and the Group — Competition and Regulatory Matters' (under the headings 'Investigations into LIBOR, ISDAfix and other Benchmarks', 'Investigations into Foreign Exchange Trading', 'Interest Rate Hedging Products Redress', 'Payment Protection Insurance Redress', 'Federal Energy Regulatory Commission Investigation', 'Credit Default Swap (CDS) Antitrust Investigations', Investigations into Certain Agreements', and 'Alternative Trading Systems and High-Frequency Trading') and 'The Issuer and the Group -Legal Proceedings' under the headings 'Lehman Brothers', 'American Depositary Shares', 'Mortgage Related Activity and Litigation', 'Devonshire Trust', 'LIBOR and other Benchmarks Civil Actions', 'Civil Action in Respect of Foreign Exchange Trading' and 'Other Legal and Regulatory Proceedings'), Note 28 (Provisions) on pages 301 to 302 of the Joint Annual Report and Note 30 (Legal, Competition and Regulatory Matters) on pages 303 to 309 of the Joint Annual Report, there are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware), which may have or have had during the 12 months preceding the date of this Base Prospectus, a significant effect on the financial position or profitability of the Issuer and/or the Group."

Terms defined in the Registration Document and the Base Prospectuses shall, unless the context otherwise requires, have the same meanings when used in the Prospectus Supplement (in relation to the Registration Document or the relevant Base Prospectus (as applicable)). This Prospectus Supplement is supplemental to, and should be read in conjunction with the Registration Document and each Base Prospectus (as applicable) and other supplements to the Registration Document and relevant Base Prospectus (as applicable). To the extent that there is any inconsistency between (a) any statement in this Prospectus Supplement (in relation to the Registration Document or any Base Prospectus (as applicable)) and (b) any other statement in, or incorporated by reference in the Registration Document or any Base Prospectus (as applicable), the statements in (a) above shall prevail.

Investors should be aware of their rights under Section 87Q(4) to (6) of the Financial Services and Markets Act 2000. Investors who have agreed to purchase or subscribe for Securities before this supplement was published have the right, exercisable within two working days after the date on which this Prospectus Supplement is published, to withdraw their acceptances. Such right shall expire on 4 July 2014. Investors should contact the distributor from which they agreed to purchase or subscribe the Securities in order to exercise their withdrawal rights.

References to the Registration Document and each Base Prospectus shall hereafter mean, respectively, the Registration Document and the relevant Base Prospectus as supplemented by this Prospectus Supplement. The Issuer has taken all reasonable care to ensure that the information contained in the Registration Document and each Base Prospectus, as supplemented by this Prospectus Supplement, is, to the best of its knowledge, in accordance with the facts and contains no omission likely to affect its import and accepts responsibility accordingly. Save as disclosed in this Prospectus Supplement, no significant new factor, material mistake or inaccuracy relating to the information included in each of the Registration Document and Base Prospectuses which is capable of affecting the assessment of the securities issued pursuant to the

Registration Document and any Base Prospectus has arisen or been noted, as the case may be, since the publication of each of the Registration Document and the Base Prospectuses (as supplemented at the date hereof) issued by the Issuer.

This Prospectus Supplement has been approved by the United Kingdom Financial Conduct Authority, which is the United Kingdom competent authority for the purposes of the Prospectus Directive and the relevant implementing measures in the United Kingdom, as a prospectus supplement issued in compliance with the Prospectus Directive and the relevant implementing measures in the United Kingdom for the purpose of giving information with regard to the issue of securities under the Programme.



The date of this Prospectus Supplement is 2 July 2014.

36189497